Barclays’s Charles River Laboratories CRL Stock Holding History

Barclays’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1,200	Closed	-$170K	–	6762
2019 Q2	$170K	Hold	1,200	–	–	﹤0.01%	5260
2019 Q1	$174K	Sell	1,200 -700	-37%	-$92K	﹤0.01%	4925
2018 Q4	$215K	Buy	+1,900	New	+$238K	﹤0.01%	4523
2014 Q3	–	Sell	-100	Closed	-$5K	–	7669
2014 Q2	$5K	Hold	100	–	–	﹤0.01%	7106
2014 Q1	$6K	Buy	+100	New	+$5.83K	﹤0.01%	7127
2013 Q4	–	Sell	-50,000	Closed	-$2.3M	–	7544
2013 Q3	$2.3M	Buy	+50,000	New	+$2.29M	﹤0.01%	2412

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Barclays's CRL Position: Q1 2026 in Review

Barclays increased its Charles River Laboratories (CRL) stake by 297% in Q1 2026, buying an estimated $32.6M and bringing the position to 234,936 shares worth $40.5M. The position accounts for 0.01% of the portfolio, ranked #801.

Barclays first reported a position in CRL in Q2 2013 and has held it in 50 quarters since. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

Barclays held 234,936 shares of Charles River Laboratories worth $40.5M as of Q1 2026.
Barclays bought 175,802 Charles River Laboratories shares in Q1 2026, an estimated $32.6M.
Charles River Laboratories made up 0.01% of Barclays's portfolio in Q1 2026, its #801 holding.
Barclays first reported a position in Charles River Laboratories in Q2 2013 and has held it in 50 quarters since.
558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.